Notable Labs is changing the landscape of how we view and treat hematological cancer, one sample at a time.

Notable Labs is changing the landscape of how we view and treat hematological cancer, one sample at a time.

U.S. Patent 2,656,508. This is the patent number for the first impedance-based flow cytometry device, using the Coulter principle issued in 1953, to Wallace H. Coulter. Mack Fulwyler was the inventor of the forerunner to today’s flow cytometers – particularly the cell sorter. In November 1965, Fulwyler introduced to the world in his Science publication […]

Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Novel precision medicine approaches such as Notable Labs’ ex vivo DSS identify rational drugs and drug combinations and predict clinical therapeutic responses

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity.

September is Blood Cancer Awareness Month

September is Blood Cancer Awareness Month

Living with Adult Acute Lymphoblastic Leukemia September is Blood Cancer Awareness Month. The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer and has helped advance 54 of the 64 blood cancer treatment options approved by the U.S. Food and Drug Administration since 2017. This month the LLS announced it […]

Emerging Treatment Approaches of High-Risk Myelodysplastic Syndrome

Emerging Treatment Approaches of High-Risk Myelodysplastic Syndrome

The Stanford University Cancer Center and the MDS Foundation are proud to bring you this complimentary webinar presented by Stanford’s Dr. Michael Spinner, post-doctoral medical fellow, oncology, and moderated by the MDS Foundation’s Sandra Kurtin, Ph.D., ANP-C, AOCN.

How We Capture Mechanism of Action in the Notable Platform

How We Capture Mechanism of Action in the Notable Platform

Notable has developed a versatile platform for testing a wide variety of drugs in patient ex vivo clinical samples, with a high-throughput flow cytometry readout that incorporates diverse phenotypes, including measures of apoptosis, proliferation, differentiation, and stemness, as well as immunotherapy targets.

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Notable’s Mission to Move Beyond a  “One-Size-Fits-All” <em>Ex Vivo</em> Drug Sensitivity Test

Notable’s Mission to Move Beyond a “One-Size-Fits-All” Ex Vivo Drug Sensitivity Test

Figure 1: Heatmap showing responses to 31 drugs or drug combinations (rows) in 37 blood cancer patient samples (columns). Each colored box represents the level of ex vivo drug sensitivity, with red indicating the highest level of sensitivity and blue the lowest. Getting the right cancer drugs to the right patients relies on the accurate […]

Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples

Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples

Prognoses for acute promyelocytic leukemia (APL) patients improved drastically upon the introduction of differentiation therapy with all-trans-retinoic acid (ATRA) in combination with conventional chemotherapy. Unfortunately, this therapeutic approach has not translated to other genetic subtypes of acute myeloid leukemia...

PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells

PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells

To identify cancer cell types that are sensitive to PTC299, a panel of 240 tumor cell lines was tested against which the concentration of compound required to reduce cell viability by 50% (CC50) was determined. Overall, the viability of 18% of cells from solid tumor(34/184) and ~57% of cells from hematologic malignancies (32/56) was reduced...

Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression

Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression

The barcodes were then used to reassemble the genetic profiles of cells from next-generation sequencing data. We applied this approach to sequential clinical MDS samples, genotyping the most clinically relevant loci across more than 15,000 individual cells. Additionally, to study effects of subclonal mutations on drug sensitivity, ex vivo functional...